Vasileios C Kyttaris1. 1. Division of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, CLS-936, Boston, MA, 02215, USA. vkyttari@bidmc.harvard.edu.
Abstract
PURPOSE OF REVIEW: The treatment of systemic lupus erythematosus (SLE) still depends on non-specific immunosuppression. Herein, we review promising targeted therapies that have the potential to change this therapeutic paradigm. RECENT FINDINGS: Besides the FDA-approved B lymphocyte stimulator (BLyS) inhibitor, belimumab, interferon-α represents a promising treatment target, albeit with modest effectiveness primarily in non-renal SLE. Preclinical and early-phase clinical trials using biologics and small molecules targeting B and T cell activation as well as the cross-talk between these cells also show promise. BLyS and interferon targeting show the most promising results in challenging the current treatment status in non-renal SLE.
PURPOSE OF REVIEW: The treatment of systemic lupus erythematosus (SLE) still depends on non-specific immunosuppression. Herein, we review promising targeted therapies that have the potential to change this therapeutic paradigm. RECENT FINDINGS: Besides the FDA-approved B lymphocyte stimulator (BLyS) inhibitor, belimumab, interferon-α represents a promising treatment target, albeit with modest effectiveness primarily in non-renal SLE. Preclinical and early-phase clinical trials using biologics and small molecules targeting B and T cell activation as well as the cross-talk between these cells also show promise. BLyS and interferon targeting show the most promising results in challenging the current treatment status in non-renal SLE.
Entities:
Keywords:
Biologics; Lupus; Small molecules; Treatment
Authors: L Kahl; J Patel; M Layton; M Binks; K Hicks; G Leon; E Hachulla; D Machado; D Staumont-Sallé; M Dickson; L Condreay; L Schifano; S Zamuner; R F van Vollenhoven Journal: Lupus Date: 2016-07-11 Impact factor: 2.911
Authors: Eduardo F Mysler; Alberto J Spindler; Renato Guzman; Marc Bijl; David Jayne; Richard A Furie; Frédéric A Houssiau; Jorn Drappa; David Close; Romeo Maciuca; Kajal Rao; Saba Shahdad; Paul Brunetta Journal: Arthritis Rheum Date: 2013-09
Authors: Chi Chiu Mok; King Yee Ying; Cheuk Wan Yim; Yui Pong Siu; Ka Hang Tong; Chi Hung To; Woon Leung Ng Journal: Ann Rheum Dis Date: 2014-12-30 Impact factor: 19.103
Authors: Andrew L Rankin; Nilufer Seth; Sean Keegan; Tatyana Andreyeva; Tim A Cook; Jason Edmonds; Nagappan Mathialagan; Micah J Benson; Jameel Syed; Yutian Zhan; Stephen E Benoit; Joy S Miyashiro; Nancy Wood; Shashi Mohan; Elena Peeva; Shashi K Ramaiah; Dean Messing; Bruce L Homer; Kyri Dunussi-Joannopoulos; Cheryl L Nickerson-Nutter; Mark E Schnute; John Douhan Journal: J Immunol Date: 2013-09-25 Impact factor: 5.422
Authors: Megan E B Clowse; Daniel J Wallace; Richard A Furie; Michelle A Petri; Marilyn C Pike; Piotr Leszczyński; C Michael Neuwelt; Kathryn Hobbs; Mauro Keiserman; Liliana Duca; Kenneth C Kalunian; Catrinel Galateanu; Sabine Bongardt; Christian Stach; Carolyn Beaudot; Brian Kilgallen; Caroline Gordon Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: Maria P Karampetsou; Denis Comte; Abel Suárez-Fueyo; Eri Katsuyama; Nobuya Yoshida; Michihito Kono; Vasileios C Kyttaris; George C Tsokos Journal: Arthritis Rheumatol Date: 2019-01 Impact factor: 10.995